Zang Yi-Wen, Gu Xiao-Dong, Xiang Jian-Bin, Chen Zong-You
Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China (mainland).
Med Sci Monit. 2014 Jun 10;20:953-9. doi: 10.12659/MSM.890496.
As an emerging therapeutic approach, adoptive T cell therapy shown promise in advanced solid malignancies. The results obtained in patients with metastatic melanoma and kidney cancer are encouraging because of the visible clinical benefits and limited adverse effects. Recently, the genetically-modified T cells expressing specific T cell receptors or chimeric antigen receptors are just now entering the clinical arena and show great potential for high avidity to tumor-associated antigens and long-lasting anti-tumor responses. However, continued investigations are necessary to improve the cell product quality so as to decrease adverse effects and clinical costs, and make adoptive T cell therapy a tool of choice for solid malignancies.
作为一种新兴的治疗方法，过继性T细胞疗法在晚期实体恶性肿瘤中显示出前景。在转移性黑色素瘤和肾癌患者中取得的结果令人鼓舞，因为有明显的临床益处且不良反应有限。最近，表达特异性T细胞受体或嵌合抗原受体的基因改造T细胞刚刚进入临床领域，并显示出对肿瘤相关抗原具有高亲和力和持久抗肿瘤反应的巨大潜力。然而，有必要继续进行研究以提高细胞产品质量，从而降低不良反应和临床成本，并使过继性T细胞疗法成为实体恶性肿瘤的首选治疗手段。
